Survival is worse in renal cancer patients who were denied new drugs, small study indicatesBMJ 2009; 339 doi: http://dx.doi.org/10.1136/bmj.b3661 (Published 09 September 2009) Cite this as: BMJ 2009;339:b3661
- Roger Dobson
Patients with renal cancer who were denied access to two new drugs, sunitinib and sorafenib, because their NHS trusts would not fund their use had worse survival outcomes than patients who were allowed the drugs, even though they were all treated by the same clinical team, a small study has shown.
The results showed that survival in patients who received the new drugs was better than in those who hadn’t applied for funding for the drugs, even though all had similar prognostic factors (hazard ratio 0.46 (95% confidence interval 0.21 to 1.01; P=0.05)) (Clinical Oncology doi:10.1016/j.clon.2009.06.007).
“This audit …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial